EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia

Ronald Palmen, Tracy Sandritter, Lindsey Malloy-Walton, Christopher Follansbee, Jonathan B Wagner

Frontiers in Pediatrics · 28.06.2023 · 11

DOI: 10.3389/fped.2023.1168619 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Pediatrics, online erschienen am 28.06.2023. Verfasst von Ronald Palmen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Children's Mercy, Kansas City, MO, United States. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Flecainide is a class IC antiarrhythmic utilized in prophylaxis of refractory paroxysmal supraventricular tachycardias in pediatric populations. Despite being a highly effective agent, its narrow therapeutic index increases the risk of toxicity and proarrhythmic events, including wide-complex tachycardia. In the absence of direct plasma sampling in the fetus to quantitate flecainide systemic concentrations, clinicians typically make drug dosing decisions from maternal plasma concentrations and QRS duration on maternal ECGs. There remains a paucity of standard guidelines and data to inform the timing and frequency of the aforementioned test in pregnancy and timing of flecainide discontinuation prior to childbirth. Flecainide primarily undergoes metabolism via cytochrome P450 (CYP). Given the variance of CYP-mediated metabolism at the level of the individual patient, pharmacogenomics can be considered in patients who present with flecainide toxicity to determine the maternal vs. fetal factors as an etiology for the event. Finally, pharmacogenetic testing can be utilized as an adjunct to guide flecainide dosing decisions, but must be done with caution in neonates <2 weeks of age. This case report highlights utilization of pharmacogenomic testing and therapeutic drug monitoring as adjuncts to guide therapy for a newborn with refractory supraventricular tachycardia, who experienced flecainide toxicity immediately post-partum and was trialed unsuccessfully on multiple alternative antiarrhythmics without rhythm control.

Schlagwörter

Stichwörter der Autor:innen

drug monitoringflecainidepharmacogeneticpharmacogenomicstoxicity

Autor:innen und Institutionen

  • Children's Mercy, Kansas City, MO, United States.
  • Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States.
  • University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States.
  • University of Missouri-Kansas City School of Pharmacy, Kansas City, MO, United States.
  • Ward Family Heart Center, Kansas City, MO, United States.
  • Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Kansas City, MO, United States.

Zitieren

APA

Palmen, R., Sandritter, T., Malloy-Walton, L., Follansbee, C., & Wagner, J. B. (2023). Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia. Frontiers in Pediatrics, 11. https://doi.org/10.3389/fped.2023.1168619

Vancouver

Palmen R, Sandritter T, Malloy-Walton L, Follansbee C, Wagner JB. Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia. Frontiers in Pediatrics. 2023;11. doi:10.3389/fped.2023.1168619

BibTeX
@article{Palmen2023,
  author = {Palmen, Ronald and Sandritter, Tracy and Malloy-Walton, Lindsey and Follansbee, Christopher and Wagner, Jonathan B},
  title = {Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia},
  journal = {Frontiers in Pediatrics},
  year = {2023},
  volume = {11},
  doi = {10.3389/fped.2023.1168619}
}
Kostenlos starten →